D
Decoy Therapeutics Inc. (DCOY)
NCM – Real Time Price. Currency in USD
5.15
-0.29 (-5.33%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.15
-0.29 (-5.33%)
At close: May 12, 2026, 4:00 PM EDT
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design α-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
| Name | Position |
|---|---|
| Dr. Barbara Hibner Ph.D. | Chief Scientific Officer |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Senior Vice President of Clinical Development |
| Mr. Frederick E. Pierce II | CEO & Director |
| Mr. Mark J. Rosenblum CPA | Executive VP of Finance & CFO |
| Mr. Peter K. Marschel M.B.A., M.S. | Chief Business Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 10-Q | dcoy-20260331.htm |
| 2026-04-30 | 10-K/A | dcoy-20251231.htm |
| 2026-04-02 | S-8 | dcoy-20260402.htm |
| 2026-04-02 | 8-K | dcoy-20260331.htm |
| 2026-03-31 | 10-K | dcoy-20251231.htm |
| 2026-03-05 | 8-K | dcoy-20260305.htm |
| 2026-02-25 | 8-K | dcoy-20260224.htm |
| 2026-01-09 | DEF 14A | d70714ddef14a.htm |
| 2026-01-08 | 8-K | flks-20260108.htm |